{"id":20927,"date":"2025-01-08T11:51:02","date_gmt":"2025-01-08T03:51:02","guid":{"rendered":"https:\/\/flcube.com\/?p=20927"},"modified":"2025-01-08T11:51:03","modified_gmt":"2025-01-08T03:51:03","slug":"merck-kgaa-adopts-quris-ais-bio-ai-platform-for-drug-development-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20927","title":{"rendered":"Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline"},"content":{"rendered":"\n

Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK<\/a>) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.<\/p>\n\n\n\n

Background of the Partnership<\/strong>
Merck and Quris AI first partnered in 2022, with Merck evaluating the Quris BioAI machine learning platform and comparing it with traditional in vitro and preclinical animal trials. The collaboration was expanded in September 2023, with Merck utilizing the company’s AI platform to assess the liver toxicity risk of candidate drugs.<\/p>\n\n\n\n

Significance of the Adoption<\/strong>
The adoption of the Quris AI platform by Merck KGaA highlights the growing importance of AI in drug development. By integrating the Bio-AI platform into its pipeline, Merck aims to enhance the efficiency and accuracy of preclinical testing, potentially reducing development time and costs while improving the overall success rate of new drug candidates.<\/p>\n\n\n\n

Future Prospects<\/strong>
This expanded partnership underscores the potential of AI-driven platforms like Quris AI to revolutionize the drug development process. As more pharmaceutical companies adopt such technologies, the industry is poised to see significant advancements in bringing innovative and effective treatments to market.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced…<\/p>\n","protected":false},"author":1,"featured_media":20929,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,1147,120,3081],"class_list":["post-20927","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-etr-mrk","tag-merck","tag-quris-ai"],"yoast_head":"\nMerck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20927\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline\" \/>\n<meta property=\"og:description\" content=\"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20927\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T03:51:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-08T03:51:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline\",\"datePublished\":\"2025-01-08T03:51:02+00:00\",\"dateModified\":\"2025-01-08T03:51:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0802.png\",\"keywords\":[\"AI\",\"ETR: MRK\",\"Merck\",\"Quris AI\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20927#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20927\",\"name\":\"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0802.png\",\"datePublished\":\"2025-01-08T03:51:02+00:00\",\"dateModified\":\"2025-01-08T03:51:03+00:00\",\"description\":\"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20927\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0802.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0802.png\",\"width\":1080,\"height\":720,\"caption\":\"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20927#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline - Insight, China's Pharmaceutical Industry","description":"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20927","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline","og_description":"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.","og_url":"https:\/\/flcube.com\/?p=20927","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-08T03:51:02+00:00","article_modified_time":"2025-01-08T03:51:03+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20927#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20927"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline","datePublished":"2025-01-08T03:51:02+00:00","dateModified":"2025-01-08T03:51:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20927"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20927#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","keywords":["AI","ETR: MRK","Merck","Quris AI"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20927#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20927","url":"https:\/\/flcube.com\/?p=20927","name":"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20927#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20927#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","datePublished":"2025-01-08T03:51:02+00:00","dateModified":"2025-01-08T03:51:03+00:00","description":"Quris AI, an artificial intelligence (AI) pharmaceutical company based in Boston and Tel-Aviv, has announced that Merck KGaA (ETR: MRK) has adopted its Bio-AI clinical prediction platform as part of the German major\u2019s drug development pipeline. This means that selected preclinical small molecule candidates will now be tested through the Quris AI platform prior to entering clinical testing.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20927#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20927"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20927#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","width":1080,"height":720,"caption":"Merck KGaA Adopts Quris AI's Bio-AI Platform for Drug Development Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20927#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA Adopts Quris AI’s Bio-AI Platform for Drug Development Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0802.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20927"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20927\/revisions"}],"predecessor-version":[{"id":20930,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20927\/revisions\/20930"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20929"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}